<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00619710</url>
  </required_header>
  <id_info>
    <org_study_id>3591IL/0079</org_study_id>
    <secondary_id>D9211C00079</secondary_id>
    <nct_id>NCT00619710</nct_id>
  </id_info>
  <brief_title>Complicated Skin and Skin Structure Infections</brief_title>
  <official_title>A Multicenter, Randomized, Double Blind, Comparative Trial of Intravenous MERREM (Meropenem, ICI 194,660) vs PRIMAXIN I.V. (Imipenem-cilastatin) in the Treatment of Hospitalised Subjects With Complicated Skin and Skin Structure Infections.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the non-inferiority of meropenem (Merrem) and
      imipenem in hospitalised subjects with complicated skin and skin structure infections.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <completion_date type="Actual">April 2004</completion_date>
  <primary_completion_date type="Actual">December 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary measure is clinical response after all antibacterial treatment is stopped).</measure>
    <time_frame>7-28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical and microbiological response</measure>
    <time_frame>Twice 3-28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Skin Infection</condition>
  <condition>Abscess</condition>
  <condition>Cellulitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Meropenem</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Imipenem-cilastatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Merrem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipenem-cilastatin</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Primaxin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects are hospitalized males and females, aged 13 years or older, with clinical
             evidence of complicated skin and skin structure bacterial infection with material
             suitable for culture from 1 primary site of infections

          -  Within 72 hours before enrollment or at the time of enrollment, all subjects must
             provide an appropriate specimen for culture and susceptibility testing

          -  Subjects who have been given prior antibacterial therapy within 14 days of trial entry
             may be entered only if a culture is obtained showing persistence of a pathogen in
             blood or at the site of infection

        Exclusion Criteria:

          -  Subjects with a known or suspected hypersensitivity to cephalosporins, penicillins, or
             carbapenems

          -  Subjects with a history of seizure disorders or subjects currently receiving
             antiepileptic medication

          -  Subjects with underlying infections or conditions which would interfere with
             evaluation of this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2008</study_first_submitted>
  <study_first_submitted_qc>February 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2008</study_first_posted>
  <last_update_submitted>August 31, 2017</last_update_submitted>
  <last_update_submitted_qc>August 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2017</last_update_posted>
  <keyword>skin infections</keyword>
  <keyword>MERREM</keyword>
  <keyword>PRIMAXIN IV</keyword>
  <keyword>complex abscess</keyword>
  <keyword>perirectal abscess</keyword>
  <keyword>wound infections</keyword>
  <keyword>infected ischemic/diabetic ulcers</keyword>
  <keyword>cellulitis</keyword>
  <keyword>Meropenem</keyword>
  <keyword>Imipenem-cilastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Abscess</mesh_term>
    <mesh_term>Skin Diseases, Infectious</mesh_term>
    <mesh_term>Cellulitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Thienamycins</mesh_term>
    <mesh_term>Imipenem</mesh_term>
    <mesh_term>Cilastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

